On Thursday, Himax Technologies, Inc. (ADR) (NASDAQ:HIMX)’s shares declined -0.27% to $7.29.
Himax Technologies, Inc. (HIMX) (“Himax” or “Company”), a leading supplier and fabless manufacturer of display drivers and other semiconductor products, recently declared the appointment of Lamnia International, LLC. at the Company’s US-based investor relations firm.
“Himax’s position as one of the top three display driver companies in the world plus their recognition as an innovator of new display technologies, necessitates approaches that assist investors understand the technology itself in addition to the Company’s opportunities,” added John Mattio, Founder and CEO of Lamnia International. “We will deliver investor communications that positions Himax’s unique market value and its resulting benefit to shareholders. We look forward to working with administration to continually communicate the Company’s successful and long-standing operations and exciting growth prospects to interested investors worldwide.”
Himax Technologies, Inc., a fabless semiconductor company, provides display imaging processing technologies to consumer electronics worldwide. The company operates through Driver IC and Non-Driver Products segments. It offers display driver integrated circuits (ICs) and timing controllers used in televisions (TVs), laptops, monitors, mobile phones, tablets, digital cameras, car navigation, and other consumer electronics devices.
American Water Operates Company Inc (NYSE:AWK)’s shares dropped -0.20% to $51.11.
American Water (AWK), the nation’s largest publicly traded water and wastewater utility company, recently declared Paul Gagliardo, M.P.H., P.E., manager of Innovation Development, will take part in the Water Innovation Summit in Berkeley, Calif. on Sept. 22-23.
Gagliardo will join other industry leaders on a panel titled “Shifting Our Behavior: The Water Mind-Set Challenge” and talk about American Water’s Innovation Development Process, the advantages of the company’s footprint and technical expertise, and some examples of American Water’s recent innovations.
American Water Operates Company, Inc., through its auxiliaries, provides water and wastewater services in the United States and Canada. The company operates through two segments, Regulated Businesses and Market-Based Operations. The Regulated Businesses segment offers water and wastewater services to about 1,600 communities in 16 states. It operates about 81 surface water treatment plants with about 500 groundwater treatment plants, 1,000 groundwater wells; 100 wastewater treatment facilities, 1,200 treated water storage facilities, 1,300 pumping stations, 89 dams, and 48,000 miles of mains and collection pipes.
At the end of Thursday’s trade, Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI)‘s shares surged 3.32% to $6.54.
Spectrum Pharmaceuticals, Inc. ( SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced publication of results from the pivotal clinical study for EVOMELA, used for myeloablative conditioning in multiple myeloma (MM) patients undergoing autologous transplantation. (ASCT). The study, led by Dr. Parameswaran Hari from Froedtert Hospital and Medical College of Wisconsin, was published in the Biology of Blood and Marrow Transplantation (BBMT) journal.
The BBMT journal publication comprises data on 61 patients who were enrolled in this open-label Phase 2b pivotal study at five US study sites; 56 patients had newly diagnosed disease and five had relapsed MM following preceding ASCT. Patients enrolled in this study received 200 mg/m2 of EVOMELA as two doses on Day -3 and Day -2 preceding to ASCT (Day 0). Efficacy was assessed by clinical response at Day +100 with an ORR of 95% and CR rate of 31% (16% stringent CRs) based on investigators’ assessments, and rates of 100% and 21%, respectively based on independent pathology review; the lower rate of confirmed CRs in the independent review was due to missing data. Importantly, the five patients who had formerly relapsed from a preceding ASCT were all shown to achieve a response to EVOMELA. All patients in the study achieved myeloablation with a median of 5 days post-ASCT, and all patients had successful neutrophil and platelet engraftment (median of 12 days and 13 days post-ASCT, respectively). Treatment-related mortality was 0%, and non-hematologic adverse events were mostly Grade 1 and Grade 2 in severity. The incidence of Grade 3 mucositis and Grade 3 stomatitis were 10% and 5%, respectively with no Grade 4 mucositis or stomatitis stated. Twenty percent of patients practiced treatment-emergent serious adverse events, most of which were Grade 3, and comprised of events commonly stated in patients undergoing myeloablative chemotherapy; no new safety signals were identified.
Spectrum Pharmaceuticals, Inc., a biotechnology company, develops and commercializes oncology and hematology drug products. The company markets five drug products, counting FUSILEV for the treatment of patients with metastatic colorectal cancer, rescue after high-dose methotrexate therapy in osteosarcoma, and to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists; FOLOTYN, a folate analogue metabolic inhibitor for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL); ZEVALIN injection for patients with follicular non-Hodgkin’s lymphoma; MARQIBO, a sphingomyelin/cholesterol liposome-encapsulated formulation of the anticancer drug vincristine for the treatment of adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia; and BELEODAQ injection for patients with relapsed or refractory PTCL.
Splunk Inc (NASDAQ:SPLK), ended its Thursday’s trading session with 1.49% gain, and closed at $60.06.
Federal Realty Investment Trust (FRT) recently declared that Splunk Inc. (NASDAQ: SPLK) executed a long-term lease for 100% of the Trust’s 500 Santana Row, a 234,500 square foot, Class-A office building under construction at Santana Row on Winchester Boulevard and Olsen Drive. With over 10,000 customers worldwide, Splunk is a provider of the leading software platform for real-time Operational Intelligence. 500 Santana Row is planned to deliver in 2016 and features six levels of office space above a four-level, below-grade parking garage containing about 670 spaces. The all concrete structure features 13-foot ceiling heights, a modern glass curtain wall, private terraces, private bicycle lockers and showers, and is built to a LEED Gold standard. 500 Santana Row was designed by WRNS Studio, a San Francisco-based architectural firm, and is being built by Devcon Construction, a Bay Area general contractor; both are managed by Federal Realty and its development consultant, Westwood Interests. Newmark Cornish & Carey represented Federal Realty and Splunk.
500 Santana Row augments the office space offering at Santana Row, building off of the success of the 65,000 square foot 300 Santana Row and an additional 50,000 square feet of office space located on the second floor above Santana Row’s shops & restaurants. Other office tenants at Santana Row comprise international commercial real estate service firm DTZ, leading apartment REIT AvalonBay Communities, healthcare provider Satellite Healthcare, cloud computing security firm Elastica, medical device firm Si-Bone, credit reporting company Experian, and others. In addition to the 234,500 square feet of Class-A office space, 500 Santana Row will add almost 500 net new parking spaces for patrons’ use on nights and weekends. Santana Row comprises 70 shops, 20 restaurants, 9 personal service businesses, 615 rental apartments, 219 residential condominiums and the 214-room boutique Hotel Valencia.
Splunk, Inc. provides software products that enable organizations to gain real-time operational intelligence in the United States and internationally. The companys products enable users to collect, index, search, explore, monitor, and analyze data regardless of format or source users. It offers Splunk Enterprise, a machine data engine with collection, indexing, search, reporting analysis, alerting, monitoring, and data administration capabilities; and Splunk Cloud service.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
